CompletedPhase 2NCT00815945
Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors
Studying Carcinosarcoma of the corpus uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AGO Study Group
- Principal Investigator
- Philipp Harter, MDKlinikum Essen Mitte
- Intervention
- PegLiposomal Doxorubicin(drug)
- Enrollment
- 41 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2008 – 2012
Study locations (15)
- Charité, Campus Virchow Klinikum, Frauenklinik, Berlin, Germany
- Malteser Krankenhaus, Gynäkologie und Geburtshilfe, Bonn, Germany
- Klinikum Bremen-Mitte gGmbH, Frauenklinik, Bremen, Germany
- Universitätsklinikum Carl Gustav Carus, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Dresden, Germany
- Evangelisches Krankenhaus Düsseldorf, Frauenklinik, Düsseldorf, Germany
- Universitätsklinikum Essen, Frauenklinik, Essen, Germany
- Klinikum der J. W. Goethe-Universität, Klinik für Gynäkologie und Geburtshilfe, Frankfurt, Germany
- University Hospital Hamburg-Eppendorf, Hamburg, Germany
- Gynäkologisch-onkologische Praxis, Hanover, Germany
- St. Vincentius Kliniken AG, Frauenklinik, Karlsruhe, Germany
- Universitätsklinikum Giessen und Marburg GmbH, Klinik für Gynäkologie, Gynäkologische Endokrinologie und Onkologie, Marburg, Germany
- Klinikum Großhadern, Frauenklinik, München, Germany
- Universitätsklinikum Tübingen, Frauenklinik, Tübingen, Germany
- Universitätsklinikum Ulm, Universitätsfrauenklinik, Ulm, Germany
- Dr. Horst Schmidt Kliniken GmbH, Klinik für Gynäkologie und gynäkologische Onkologie, Wiesbaden, Germany
Collaborators
Merck Sharp & Dohme LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00815945 on ClinicalTrials.govOther trials for Carcinosarcoma of the corpus uteri
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07029399A Study With NKT5097 for Adults With Advanced/Metastatic Solid TumorsNiKang Therapeutics, Inc.
- RECRUITINGPHASE2NCT05619913EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine CarcinosarcomaAustralia New Zealand Gynaecological Oncology Group
- ACTIVE NOT RECRUITINGPHASE2NCT05147558A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine CarcinosarcomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1, PHASE2NCT03686124ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid TumorsImmatics US, Inc.